

*Start Time of Meeting:* Approximately 10:00 a.m.

**FOR FURTHER INFORMATION CONTACT:**

Lieutenant Colonel Edward C. Clarke,  
United States Military Academy, West  
Point, NY 10996-5000, (845) 938-4200.

**SUPPLEMENTARY INFORMATION:** *Proposed Agenda:* Organizational Meeting of the Board of Visitors. Review of the Academic, Military and Physical Programs, and the Bicentennial Campaign at the USMA. All proceedings are open.

**Edward C. Clarke,**

*Lieutenant Colonel, U.S. Army, Executive  
Secretary, USMA Board of Visitors.*

[FR Doc. 02-1647 Filed 1-22-02; 8:45 am]

**BILLING CODE 3710-08-M**

## DEPARTMENT OF DEFENSE

### Department of the Army

#### **Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Method and Kit for Detection of Dengue Virus**

**AGENCY:** U.S. Army Medical Research  
and Materiel Command, DOD.

**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 6,190,859 entitled "Method and Kit for Detection of Dengue Virus" issued 02/20/01. This patent has been assigned to the United States Government as represented by the Secretary of the Army.

**ADDRESSES:** Commander, U.S. Army  
Medical Research and Materiel  
Command, ATTN: Command Judge  
Advocate, MCMR-JA, 504 Scott Street,  
Fort Detrick, Frederick, Maryland  
21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For  
patent issues, Ms. Elizabeth Arwine,  
Patent Attorney, (301) 619-7808. For  
licensing issues, Dr. Paul Mele, Office of  
Research & Technology Assessment,  
(301) 619-6664. Both at telefax (301)  
619-5034.

**SUPPLEMENTARY INFORMATION:** An  
inactivated dengue virus vaccine to  
immunize and protect humans against  
dengue fever is described. The vaccine  
is based on dengue viruses which have  
been propagated to high titers in  
suitable cells, purified and inactivated  
under conditions which destroy  
infectivity but preserve  
immunogenicity, a high level of which  
is demonstrated in animal models. Uses  
of the inactivated dengue virus for

detecting antibodies to dengue and kits  
therefore are also described.

**Luz D. Ortiz,**

*Army Federal Register Liaison Officer.*

[FR Doc. 02-1643 Filed 1-22-02; 8:45 am]

**BILLING CODE 3710-08-M**

## DEPARTMENT OF DEFENSE

### Department of the Army

#### **Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning DNA Vaccines Against Tick-Borne Flaviviruses**

**AGENCY:** U.S. Army Medical Research  
and Materiel Command, DOD.

**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 6,258,788 entitled "DNA Vaccines Against Tick-Borne Flaviviruses" issued 07/10/01. Foreign rights also available (PCT/US98/25322). This patent has been assigned to the United States Government as represented by the Secretary of the Army.

**ADDRESSES:** Commander, U.S. Army  
Medical Research and Materiel  
Command, ATTN: Command Judge  
Advocate, MCMR-JA, 504 Scott Street,  
Fort Detrick, Frederick, Maryland  
21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For  
patent issues, Ms. Elizabeth Arwine,  
Patent Attorney, (301) 619-7808. For  
licensing issues, Dr. Paul Mele, Office of  
Research & Technology Assessment,  
(301) 619-6664. Both at telefax (301)  
619-5034.

**SUPPLEMENTARY INFORMATION:** Particle  
mediated immunization of tick-borne  
*flavivirus genes* confers homologous and  
heterologous protection against tick  
borne encephalitis.

**Luz D. Ortiz,**

*Army Federal Register Liaison Officer.*

[FR Doc. 02-1642 Filed 1-22-02; 8:45 am]

**BILLING CODE 3710-08-M**

## DEPARTMENT OF DEFENSE

### Department of the Army

#### **Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Indolo[2,1-b]quinazoline-6, 12-dione Antimalarial Compounds and Methods of Treating Malaria**

**AGENCY:** U.S. Army Medical Research  
and Materiel Command, DOD.

**ACTION:** Notice.

**SUMMARY:** In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 6,284,772 entitled "Indolo[2,1-b]quinazoline-6, 12-dione antimalarial compounds and Methods of Treating Malaria" issued 09/04/01. Foreign rights are also available (PCT/US99/22569). This patent has been assigned to the United States Government as represented by the Secretary of the Army.

**ADDRESSES:** Commander, U.S. Army  
Medical Research and Materiel  
Command, ATN: Command Judge  
Advocate, MCMR-JA, 504 Scott Street,  
Fort Detrick, Frederick, Maryland  
21702-5012.

**FOR FURTHER INFORMATION CONTACT:** For  
patent issues, Ms. Elizabeth Arwine,  
Patent Attorney, (301) 619-7808. For  
licensing issues Dr. Paul Mele, Office of  
Research & Technology Assessment,  
(301) 619-6664. Both at telefax (301)  
619-5034.

**SUPPLEMENTARY INFORMATION:**  
Compounds, compositions and methods  
are provided for treating malaria  
parasites in vitro and in vivo by  
administering indolo [2,1-  
b]quinazoline-6, 12-dione compounds of  
Formula 1. On Formula 1 A, B, C, D, E,  
F, G and H are independently selected  
from carbon and nitrogen, or A and B  
or C and D can be taken together to be  
nitrogen or sulfur, with the proviso that  
not more than three of A, B, C, D, E, F,  
G and H are other than carbon; wherein  
R1 through R8 are independently  
selected from the group consisting of,  
but not limited to, the halogens, alkyl  
groups, trifluoromethyl groups,  
methoxyl groups, the carboxy methyl or  
carboxy ethyl group, nitro, aryl,  
heteroaryl, cyano, amino,  
dialkylaminoalkyl, 1-(4-  
alkylpiperazinyl), and the  
pharmaceutically acceptable salts  
thereof; and wherein X is independently  
selected from the group consisting of  
any atom especially oxygen, or any side  
chain necessary to make the indolo[2,1-  
b]quinazoline-6, 12-dione compound a  
"prodrug" as the term is understood by  
one of ordinary skill in the art of  
medicinal chemistry. In other words, a  
side chain having a structure where a  
carbon-nitrogen double bond bears  
substituents that make the prodrug more  
water soluble and bioavailable.

**Luz D. Ortiz,**

*Army Federal Register Liaison Officer.*

[FR Doc. 02-1645 Filed 1-22-02; 8:45 am]

**BILLING CODE 3710-08-M**